RT Journal Article
T1 Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium.
A1 Robbins, Hilary A
A1 Ferreiro-Iglesias, Aida
A1 Waterboer, Tim
A1 Brenner, Nicole
A1 Nygard, Mari
A1 Bender, Noemi
A1 Schroeder, Lea
A1 Hildesheim, Allan
A1 Pawlita, Michael
A1 D'Souza, Gypsyamber
A1 Visvanathan, Kala
A1 Langseth, Hilde
A1 Schlecht, Nicolas F
A1 Tinker, Lesley F
A1 Agalliu, Ilir
A1 Wassertheil-Smoller, Sylvia
A1 Ness-Jensen, Eivind
A1 Hveem, Kristian
A1 Grioni, Sara
A1 Kaaks, Rudolf
A1 Sanchez-Perez, Maria-Jose
A1 Weiderpass, Elisabete
A1 Giles, Graham G
A1 Milne, Roger L
A1 Cai, Qiuyin
A1 Blot, William J
A1 Zheng, Wei
A1 Weinstein, Stephanie J
A1 Albanes, Demetrius
A1 Huang, Wen-Yi
A1 Freedman, Neal D
A1 Kreimer, Aimée R
A1 Johansson, Mattias
A1 Brennan, Paul
K1 Female
K1 Papillomaviridae
K1 Papillomavirus Infections
K1 Oropharyngeal Neoplasms
AB Seropositivity for the HPV16-E6 oncoprotein is a promising marker for early detection of oropharyngeal cancer (OPC), but the absolute risk of OPC after a positive or negative test is unknown. We constructed an OPC risk prediction model that integrates (1) relative odds of OPC for HPV16-E6 serostatus and cigarette smoking from the human papillomavirus (HPV) Cancer Cohort Consortium (HPVC3), (2) US population risk factor data from the National Health Interview Survey, and (3) US sex-specific population rates of OPC and mortality. The nine HPVC3 cohorts included 365 participants with OPC with up to 10 years between blood draw and diagnosis and 5,794 controls. The estimated 10-year OPC risk for HPV16-E6 seropositive males at age 50 years was 17.4% (95% CI, 12.4 to 28.6) and at age 60 years was 27.1% (95% CI, 19.2 to 45.4). Corresponding 5-year risk estimates were 7.3% and 14.4%, respectively. For HPV16-E6 seropositive females, 10-year risk estimates were 3.6% (95% CI, 2.5 to 5.9) at age 50 years and 5.5% (95% CI, 3.8 to 9.2) at age 60 years and 5-year risk estimates were 1.5% and 2.7%, respectively. Over 30 years, after a seropositive result at age 50 years, an estimated 49.9% of males and 13.3% of females would develop OPC. By contrast, 10-year risks among HPV16-E6 seronegative people were very low, ranging from 0.01% to 0.25% depending on age, sex, and smoking status. We estimate that a substantial proportion of HPV16-E6 seropositive individuals will develop OPC, with 10-year risks of 17%-27% for males and 4%-6% for females age 50-60 years in the United States. This high level of risk may warrant periodic, minimally invasive surveillance after a positive HPV16-E6 serology test, particularly for males in high-incidence regions. However, an appropriate clinical protocol for surveillance remains to be established.
PB American Society of Clinical Oncology
YR 2022
FD 2022-06-14
LK http://hdl.handle.net/10668/20387
UL http://hdl.handle.net/10668/20387
LA en
NO Robbins HA, Ferreiro-Iglesias A, Waterboer T, Brenner N, Nygard M, Bender N, et al. Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. J Clin Oncol. 2022 Nov 1;40(31):3613-3622.
DS RISalud
RD Apr 4, 2025